Top

Current Hematologic Malignancy Reports

Published in:

01-04-2020 | Essential Thrombocytosis | Myeloproliferative Neoplasms (B Stein, Section Editor)

Myeloproliferative Neoplasms in Children, Adolescents, and Young Adults

Author: Nicole Kucine

Published in: Current Hematologic Malignancy Reports | Issue 2/2020

Abstract

Purpose of Review

Myeloproliferative neoplasms are traditionally seen in older adults, making them poorly understood in younger patients. Clinical presentation, genetic landscape, outcomes, and best management practices are inadequately described in this group. Over the past decade, more research has focused on younger patients, and this paper seeks to review and describe the current status of the field.

Recent Findings

A recent review analyzed the available pediatric MPN literature and highlighted the paucity of published data. Pediatric patients showed lower rates of the common mutations found in adults, thrombotic events, and disease transformation to myelofibrosis and acute leukemia. A number of centers have recently shared their experience with young adult patients. Better survival outcomes were confirmed for young adult patients compared to older patients.

Summary

There is still much to learn about myeloproliferative neoplasms in pediatric and young adult patients, but currently available data showing better outcomes is reassuring.

Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosince kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387–97. https://doi.org/10.1016/j.ccr.2005.03.023.CrossRefPubMed

Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108(10):3472–6.CALR paper. https://doi.org/10.1182/blood-2006-04-018879.CrossRefPubMed

Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391–405. https://doi.org/10.1056/NEJMoa1312542.CrossRefPubMedPubMedCentral

Nangalia J, Green TR. The evolving genomic landscape of myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program. 2014;2014(1):287–96. https://doi.org/10.1182/asheducation-2014.1.287.CrossRefPubMed

Barbui T. How to manage children and young adults with myeloproliferative neoplasms. Leukemia. 2012 Jul;26(7):1452–7. https://doi.org/10.1038/leu.2012.12.CrossRefPubMed

•• Ianotto JC, Curto-Garcia N, Lauermannova M, Radia D, Kiladjian JJ, Harrison CN. Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age, a systematic review. Haematologica. 2019. https://doi.org/10.3324/haematol.2018.200832. Systematic review on pediatric MPNs.

Hofmann I. Myeloproliferative neoplasms in children. J Hematop. 2015;8(3):143–57. https://doi.org/10.1007/s12308-015-0256-1.CrossRefPubMedPubMedCentral

• DeLario M, Sheehan AM, Ataya R, Bertuch AA, Vega C 2nd, Webb CR, et al. Clinical, histopathologic, and genetic features of pediatric primary myelofibrosis--an entity different from adults. Am J Hematol. 2012;87(5):461–4. https://doi.org/10.1002/ajh.23140. Case series of pediatric PMF patients.

• An W, Wan Y, Guo Y, Chen X, Ren Y, Zhang J, et al. CALR mutation screening in pediatric primary myelofibrosis. Pediatr Blood Cancer. 2014;61(12):2256–62. https://doi.org/10.1002/pbc.25211. Case series of pediatric PMF patients.

10.

Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, LeBeau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405. https://doi.org/10.1182/blood-2016-03-643544.CrossRefPubMed

11.

Putti MC, Pizzi M, Bertozzi I, Sabattini E, Micalizzi C, Farruggia P, et al. Bone marrow histology for the diagnosis of essential thrombocythemia in children: a multicenter Italian study. Blood. 2017 Jun 1;129(22):3040–2. https://doi.org/10.1182/blood-2017-01-761767.CrossRefPubMed

12.

• Kucine N, Al-Kawaaz M, Hajje D, Bussel J, Orazi A. Difficulty distinguishing essential thrombocythaemia from polycythaemia vera in children with JAK2 V617F-positive myeloproliferative neoplasms. Br J Haematol. 2019;185(1):136–9. Paper detailing issues with WHO diagnostic criteria when used in children.

13.

Martin K. Risk factors for and management of MPN-associated bleeding and thrombosis. Curr Hematol Malig Rep. 2017 Oct;12(5):389–96. https://doi.org/10.1007/s11899-017-0400-3.CrossRefPubMed

14.

Ishida H, Sarashina T, Matsumara R, Umeda K, Mitsui T, Fujita N, et al. Clinical features of children with polycythemia vera, essential thrombocythemia, and primary myelofibrosis in Japan: retrospective nationwide survey. Blood. 2019;134(Supplement_1):2958. https://doi.org/10.1182/blood-2019-123429.CrossRef

15.

Rampal R, Ahn J, Abdel-Wahab O, Nahas M, Wang K, Lipson D, et al. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proc Natl Acad Sci U S A. 2014;111(50):E5401–10. https://doi.org/10.1073/pnas.1407792111.CrossRefPubMedPubMedCentral

16.

Yogarajah M, Teffer A. Leukemic transformation in myeloproliferative neoplasms: a literature review on risk, characteristics, and outcome. Mayo Clin Proc. 2017;92(7):1118–28.CrossRef

17.

• Giona F, Teofili L, Moleti ML, Martini M, Palumbo G, Amendola A. Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome. Blood. 2012;119(10):2219–27. https://doi.org/10.1182/blood-2011-08-371328. Case series of pediatric ET and PV with management recommendations.

18.

Kucine N, Chastain KM, Mahler MB, Bussel JB. Primary thrombocytosis in children. Haematologica. 2014;99(4):620–8.CrossRef

19.

Randi ML, Bertozzi I, Putti MC. Contemporary management of essential thrombocythemia in children. Expert Rev Hematol. 2019;12(5):367–73.CrossRef

20.

Mesa RA, Jamieson C, Bhatia R, Deininger MW, Fletcher CD, Gerds AT, et al. NCCN guidelines insights: myeloproliferative neoplasms, version 2.2018. J Natl Compr Cancer Netw. 2017;15(10):1193–207.CrossRef

21.

Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32(5):1057–69 Hans IFN.CrossRef

22.

Pizzi M, Silver RT, Barel A, Orazi A. Recombinant interferon-α in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response. Mod Pathol. 2015 Oct;28(10):1315–23. https://doi.org/10.1038/modpathol.2015.93.CrossRefPubMed

23.

Ianotto JC, Chauveau A, Boyer-Perrard F, Gyan E, Laribi K, Cony-Makhoul P, et al. Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study. Haematologica. 2018;103(3):438–46. https://doi.org/10.3324/haematol.2017.181297.CrossRefPubMedPubMedCentral

24.

Liberek A, Łuczak G, Korzon M, Szlagatys-Sidorkiewicz A, Bako W, Góra-Gębka M, et al. Tolerance of interferon-alpha therapy in children with chronic hepatitis B. J Paediatr Child Health. 2004;40(5–6):265–9. https://doi.org/10.1111/j.1440-1754.2004.00361.x.CrossRefPubMed

25.

Navid F, Herzog CE, Sandoval J, Daryani VM, Stewart CF, Gattuso J, et al. Feasibility of pegylated interferon in children and young adults with resected high-risk melanoma. Pediatr Blood Cancer. 2016;63(7):1207–13. Published online 2016 Apr 1. https://doi.org/10.1002/pbc.25983.CrossRefPubMedPubMedCentral

26.

Kucine N, Bergmann S, Krichevsky S, Jones D, Rytting ME, Resar L. Use of pegylated interferon in six pediatric patients with myeloproliferative neoplasms. Blood. 2019;134(Supplement_1):4194. https://doi.org/10.1182/blood-2019-124023.CrossRef

27.

Loh ML, Tasian SK, Rabin KR, Brown P, Magoon D, Reid JM, et al. A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: a children’s oncology group phase 1 consortium study (ADVL1011). Pediatr Blood Cancer. 2015;62(10):1717–24. https://doi.org/10.1002/pbc.25575.CrossRefPubMedPubMedCentral

28.

• Ginzburg YZ, Feola M, Zimran E, Varkonyi J, Ganz T, Hoffman R. Dysregulated iron metabolism in polycythemia vera: etiology and consequences. Leukemia. 2018;32(10):2105–16. Excellent review paper describing iron deficiency in PV.

29.

Halterman JS, Kaczorowski JM, Aligne CA, Auinger P, Szilagyi PG. Iron deficiency and cognitive acheivement among school-aged children and adolescents in the United States. Pediatrics. 2001;107(6):1381–6. https://doi.org/10.1542/peds.107.6.1381.CrossRefPubMed

30.

Low M, Farrell A, Biggs BA, Pasricha SR. Effects of daily iron supplementation in primary-school-aged children: systematic review and meta-analysis of randomized controlled trials. CMAJ. 2013 Nov 19;185(17):E791–802. https://doi.org/10.1503/cmaj.130628.CrossRefPubMedPubMedCentral

31.

•• Boddu P, Masarova L, Verstovsek S, Strati P, Kantjarian H, Cortes J, et al. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms. Ann Hematol. 2018;97(1):109–21. https://doi.org/10.1007/s00277-017-3165-9. Large retrosepctive study of young adult patients with PV, ET, and PMF.

32.

•• Szuber N, Vallapureddy RR, Penna D, Lasho TL, Finke C, Hanson CA, et al. Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger. Am J Hematol. 2018 Dec;93(12):1474–84. https://doi.org/10.1002/ajh.25270. Large retrospective study comparing young adults with patients of older ages with PV, ET, and PMF.

33.

• Barzilai M, Kirgner I, Avivi I, Ellis M, Dally N, Rozovski U, et al. Characteristics and outcomes of young adults with Philadelphia-negative myeloproliferative neoplasms. Eur J Haematol. 2019;102(6):504–8. https://doi.org/10.1111/ejh.13232. Retrospective study of young adult MPNs.

34.

• Stein BL, Saraf S, Sobol U, Halpern A, Shammo J, Rondelli D, et al. Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. Leuk Lymphoma. 2013;54(9):1989–95. https://doi.org/10.3109/10428194.2012.759656. Study comparing young adult and older adult patients with PV.

35.

• Palandri F, Latagliata R, Polverelli N, Tieghi A, Crugnola M, Martino B, et al. Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis. Leukemia. 2015;29(6):1344–9. https://doi.org/10.1038/leu.2015.87. Large case series on young adult MPN patients.

36.

Harrison CN, Robinson SE. Myeloproliferative disorders in pregnancy. Hematol Oncol Clin North Am. 2011;25(2):261–75, vii. https://doi.org/10.1016/j.hoc.2011.01.008.CrossRefPubMed

37.

•• Maze D, Kazi S, Gupta V, Malinowski AK, Fazelzad R, Shah PS, et al. Association of treatments for myeloproliferative neoplasms during pregnancy with birth rates and maternal outcomes: a systematic review and meta-analysis. JAMA Netw Open. 2019;2(10):e1912666. https://doi.org/10.1001/jamanetworkopen.2019.12666. Systematic review on pregnancy and MPNs.

Title: Myeloproliferative Neoplasms in Children, Adolescents, and Young Adults
Author: Nicole Kucine
Publication date: 01-04-2020
Publisher: Springer US
Keywords: Essential Thrombocytosis
Primary Myelofibrosis
Primary Myelofibrosis
Published in: Current Hematologic Malignancy Reports / Issue 2/2020
Print ISSN: 1558-8211
Electronic ISSN: 1558-822X
DOI: https://doi.org/10.1007/s11899-020-00571-8

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 2/2020

Patient-Reported Outcomes in Myelodysplastic Syndromes: the Move from Life Span to Health Span

Is There a Role for Chemotherapy in the Era of Targeted Therapies?

Monoclonal Gammopathy of Undetermined Significance: Current Concepts and Future Prospects

MLL-Rearranged Acute Lymphoblastic Leukemia

Moving Past Ganciclovir and Foscarnet: Advances in CMV Therapy

Extramedullary Disease in Multiple Myeloma

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage